Vizgen Issued a New US Patent for Its MERFISH Technology
CAMBRIDGE, Mass. April 16, 2024 Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, announced today the issuance by the US Patent Office of a patent that covers the in situ imaging of the spatial transcriptome. U.S. Patent No. 11,959,075 is for robust multiplex imaging of RNA and its spatial organization in a sample.
“This latest patent relates to our MERFISH technology and enables groundbreaking advancements in the spatial genomics landscape,” said Terry Lo, CEO, Vizgen, Inc. “It is another patent underscoring Vigen’s leadership in the field, providing the industry’s best tools for single-cell spatial biology, and driving discoveries aimed at improving human health,” he said. Vizgen has secured key patents protecting its innovative pioneering technology in the United States and abroad, adding to its growing patent portfolio as Vizgen continues to invest in the development of its groundbreaking technologies. This newly allowed patent is owned by The President and Fellows of Harvard College and is exclusively licensed to Vizgen.
Reflecting its long-term commitment to scientific innovation and biomedical progress, and despite attempts by others to monopolize the field by aggressive litigation tactics, Vizgen is making the newly issued patent available for licensing.
The issuance of the ‘075 Patent comes just over a month after the PTAB denied institution of an Inter Partes Review filed by 10X Genomics, Inc. of the parent patent, U.S. Patent No. 11,098,303 also directed to the pioneering technology invented in the laboratory of Dr. Xiaowei Zhuang at Harvard University.
To date, there are over two hundred peer-reviewed and preprint publications on MERFISH technology and thousands of samples have been processed on MERSCOPE instruments. During AACR 2024, Vizgen unveiled the MERSCOPE® Ultra Platform and shared new MERFISH 2.0 chemistry data. These powerful tools are uniquely suited to supporting basic and translational research and will be commercially available in the second half of the year.
About Vizgen®
Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics. The company has established the benchmark in spatial genomics and continues to drive industry innovation, delivering the highest sensitivity as well as excellent specificity and accuracy in cell segmentation. These tools enable researchers to gain new insight into the biological systems that govern human health and disease with spatial context. Vizgen’s MERSCOPE®Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development. For more information, go to www.vizgen.com. Connect on social media Twitter, LinkedIn and Facebook.
Contacts
Vizgen:
Brittany Auclair
Vizgen
Brittany.auclair@vizgen.com